Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic and clinical evaluation.

Autor: Darlow CA; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, UK., Hope W; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, UK., Dubey V; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, UK.

Publikováno v: Expert opinion on drug metabolism & toxicology [Expert Opin Drug Metab Toxicol] 2024 Nov 07. Date of Electronic Publication: 2024 Nov 07.

Susceptibility of OXA-48-like-producing Enterobacterales to flomoxef.

Autor: Owen V; Antimicrobial Pharmacodynamics and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom; Department of Microbiology, Liverpool Clinical Laboratories, Liverpool University National Health Service Foundation Trust, Liverpool, United Kingdom; Blizard Institute, Queen Mary University of London, London, United Kingdom., Harper N; Antimicrobial Pharmacodynamics and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Dubey V; Antimicrobial Pharmacodynamics and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Gerada A; Antimicrobial Pharmacodynamics and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom; Department of Microbiology, Liverpool Clinical Laboratories, Liverpool University National Health Service Foundation Trust, Liverpool, United Kingdom., Boyd SE; Antimicrobial Pharmacodynamics and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom; Infection Clinical Academic Group, St. George's University Hospital National Health Service Foundation Trust, London, United Kingdom; National Institute for Healthcare Research Health Protection Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom., Darlow CA; Antimicrobial Pharmacodynamics and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom; Department of Microbiology, Liverpool Clinical Laboratories, Liverpool University National Health Service Foundation Trust, Liverpool, United Kingdom. Electronic address: cdarlow@liverpool.ac.uk.

Publikováno v: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2024 Jul 26. Date of Electronic Publication: 2024 Jul 26.

Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa .

Autor: Farrington N; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Dubey V; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Johnson A; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Horner I; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Stevenson A; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Unsworth J; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Jimenez-Valverde A; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Schwartz J; Charles River Laboratories, Reno, Nevada, USA., Das S; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Hope W; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom., Darlow CA; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.

Publikováno v: MBio [mBio] 2024 Feb 14; Vol. 15 (2), pp. e0316523. Date of Electronic Publication: 2024 Jan 18.

Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.

Autor: Darlow CA, Hope W

Publikováno v: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2022 Jun 29; Vol. 77 (7), pp. 2049.

Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance.

Autor: Darlow CA; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, UK., Farrington N; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, UK., Johnson A; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, UK., McEntee L; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, UK., Unsworth J; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, UK., Jimenez-Valverde A; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, UK., Kolamunnage-Dona R; Department of Health Data Science, University of Liverpool, Liverpool Health Partners, UK., Da Costa RMA; Global Antibiotic Research and Development Partnership, 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland., Ellis S; Global Antibiotic Research and Development Partnership, 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland., Franceschi F; Global Antibiotic Research and Development Partnership, 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland., Sharland M; Paediatric Infectious Diseases Research Group, St George's, University of London, UK., Neely M; Children's Hospital Los Angeles and the Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Piddock LJV; Global Antibiotic Research and Development Partnership, 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland., Das S; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, UK., Hope W; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, UK.

Publikováno v: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2022 Apr 27; Vol. 77 (5), pp. 1334-1343.